Kevin Y. Heo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kevin Y. Heo has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Ajay Premkumar
Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA, USA
13 shared publicationsGeorge N. Guild
Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA, USA
6 shared publicationsJacob M. Wilson
Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA, USA
6 shared publicationsAndrew Fuqua
Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, USA
4 shared publicationsAnthony L. Karzon
Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA, USA
4 shared publicationsAyomide M. Ayeni
Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, Georgia
4 shared publications
Latest Publications
- Open Access
- 16 May 2026
- Published by Elsevier in JSES International
- Vol. 10  (4)
Selective serotonin re-uptake inhibitors and risks of post-operative hematoma after elbow fracture surgery
- 16 May 2026
- Published by Elsevier in JSES International
- Vol. 10  (4)
Open AccessSelective serotonin re-uptake inhibitors and risks of post-operative hematoma after elbow fracture surgery
- Open Access
- 10 February 2026
- Published by Elsevier in JSES International
- Vol. 10  (3) , 101656
Implant prices and physician reimbursement have declined more than total costs and hospital payments in total shoulder arthroplasty
- 10 February 2026
- Published by Elsevier in JSES International
- Vol. 10  (3) , 101656
Open AccessImplant prices and physician reimbursement have declined more than total costs and hospital payments in total shoulder arthroplasty
- Open Access
- 9 February 2026
- Published by Elsevier in Arthroplasty Today
- Vol. 38, 101958
Outcomes of Unicompartmental Knee Arthroplasty in Patients Receiving Glucagon-like Peptide 1 Agonist Therapy: A Matched Cohort Study
- 9 February 2026
- Published by Elsevier in Arthroplasty Today
- Vol. 38, 101958
Open AccessOutcomes of Unicompartmental Knee Arthroplasty in Patients Receiving Glucagon-like Peptide 1 Agonist Therapy: A Matched Cohort Study
- 4 January 2026
- Published by SAGE Publications in Foot & Ankle Specialist
Increasing Cumulative Cases and Surgical Incidence of Charcot Neuroarthropathy in the United States From 2009 to 2019
Background. Charcot neuroarthropathy (CN) is a rare joint destructive process that occurs in the setting of peripheral neuropathy. CN can cause deformity and joint instability and has been shown to decrease quality of life. Given the rarity but severity of this condition, a better understanding of the epidemiology and treatment trends are needed. Therefore, the purpose of this study was to explore recent trends in the observed cumulative burden of CN as well as the incidence of different surgical treatments. Methods. This study utilized a large commercial insurance claims database to estimate the diagnostic cumulative burden of CN from 2009 to 2019. Patients were identified through International Classification of Disease codes. Current procedural terminology (CPT) codes were cross-matched with diagnostic codes to identify patients who underwent surgical procedures related to their CN. Incidence rates of procedures were calculated to assess for trends in management, stratified by age, sex, and geographic region. Results. From 2009 to 2019, the cumulative case rate of CN increased from 2.96 to 5.00 patients per 10 000 people (estimated 12 836 observed cases starting in 2009 to 167 145 observed cumulative cases by 2019) in the United States. In this time period, the total incidence of surgical procedures performed for these patients increased from 4.35 to 9.70 procedures per 100 000 person-years. The most common procedures included debridement and excision/resection procedures (75.21%) and arthrodesis or osteotomy procedures (9.85%). Conclusion. Current epidemiological trends for CN are not well known. This study demonstrated an increasing case burden of CN within the United States, alongside increasing incidences of surgical procedures for this disease. These trends provide important insights for patient-specific and public health advocacy. Future studies should continue to explore the contributory financial, cultural, and educatory factors of this disease. Levels of Evidence: III Retrospective cohort study
- 4 January 2026
- Published by SAGE Publications in Foot & Ankle Specialist
Increasing Cumulative Cases and Surgical Incidence of Charcot Neuroarthropathy in the United States From 2009 to 2019
Background. Charcot neuroarthropathy (CN) is a rare joint destructive process that occurs in the setting of peripheral neuropathy. CN can cause deformity and joint instability and has been shown to decrease quality of life. Given the rarity but severity of this condition, a better understanding of the epidemiology and treatment trends are needed. Therefore, the purpose of this study was to explore recent trends in the observed cumulative burden of CN as well as the incidence of different surgical treatments. Methods. This study utilized a large commercial insurance claims database to estimate the diagnostic cumulative burden of CN from 2009 to 2019. Patients were identified through International Classification of Disease codes. Current procedural terminology (CPT) codes were cross-matched with diagnostic codes to identify patients who underwent surgical procedures related to their CN. Incidence rates of procedures were calculated to assess for trends in management, stratified by age, sex, and geographic region. Results. From 2009 to 2019, the cumulative case rate of CN increased from 2.96 to 5.00 patients per 10 000 people (estimated 12 836 observed cases starting in 2009 to 167 145 observed cumulative cases by 2019) in the United States. In this time period, the total incidence of surgical procedures performed for these patients increased from 4.35 to 9.70 procedures per 100 000 person-years. The most common procedures included debridement and excision/resection procedures (75.21%) and arthrodesis or osteotomy procedures (9.85%). Conclusion. Current epidemiological trends for CN are not well known. This study demonstrated an increasing case burden of CN within the United States, alongside increasing incidences of surgical procedures for this disease. These trends provide important insights for patient-specific and public health advocacy. Future studies should continue to explore the contributory financial, cultural, and educatory factors of this disease. Levels of Evidence: III Retrospective cohort study
- 31 December 2025
- Published by Elsevier in The Spine Journal
- Vol. 26  (5) , 882-892
Glucagon-like peptide-1 receptor agonist use and perioperative outcomes after anterior cervical discectomy and fusion: a propensity-matched cohort study
- 31 December 2025
- Published by Elsevier in The Spine Journal
- Vol. 26  (5) , 882-892
Glucagon-like peptide-1 receptor agonist use and perioperative outcomes after anterior cervical discectomy and fusion: a propensity-matched cohort study
- Open Access
- 2 May 2025
- Published by Springer Nature in Arthroplasty
- Vol. 7  (1) , 1-9
The subjective hip value: a retrospective validation study in primary total hip arthroplasty
Background: The hip dysfunction and osteoarthritis outcome score for joint replacement (HOOS JR) has been widely used to assess patient hip function. The subjective hip value (SHV) has become increasingly recognized as an efficient single-question survey for assessing hip joint function. This study aimed to determine the psychometric properties of the SHV in evaluating hip function in patients undergoing total hip arthroplasty (THA) in correlation with the traditional HOOS JR. Methods: This was a retrospective review of 1,157 distinct patients who underwent primary THA between January 2021 and December 2023. Scores for SHV and HOOS JR were collected preoperatively, as well as 3 months and 1 year postoperatively. Validity was determined using Pearson’s correlation tests between the SHV and HOOS JR. Results: Overall, the SHV was highly correlated with the HOOS JR at 3 months (R = 0.71, P < 0.001) and 1 year postoperatively (R = 0.79, P < 0.001). Additionally, changes in the SHV showed significant correlations with changes in the HOOS JR between the preoperative and postoperative periods. The SHV also had substantially fewer ceiling effects compared to the HOOS JR. Conclusions: The SHV is a valid and responsive single-item assessment for hip joint function following primary THA. Despite its limitations, its efficiency and ease of use make it a feasible option for routine clinical assessments, providing clinicians with valuable insights into patients' recovery. Subsequently, the integration of the SHV into orthopedic practice holds promise for enhancing the management of postoperative care and improving patient outcomes.
- 2 May 2025
- Published by Springer Nature in Arthroplasty
- Vol. 7  (1) , 1-9
Open AccessThe subjective hip value: a retrospective validation study in primary total hip arthroplasty
Background: The hip dysfunction and osteoarthritis outcome score for joint replacement (HOOS JR) has been widely used to assess patient hip function. The subjective hip value (SHV) has become increasingly recognized as an efficient single-question survey for assessing hip joint function. This study aimed to determine the psychometric properties of the SHV in evaluating hip function in patients undergoing total hip arthroplasty (THA) in correlation with the traditional HOOS JR. Methods: This was a retrospective review of 1,157 distinct patients who underwent primary THA between January 2021 and December 2023. Scores for SHV and HOOS JR were collected preoperatively, as well as 3 months and 1 year postoperatively. Validity was determined using Pearson’s correlation tests between the SHV and HOOS JR. Results: Overall, the SHV was highly correlated with the HOOS JR at 3 months (R = 0.71, P < 0.001) and 1 year postoperatively (R = 0.79, P < 0.001). Additionally, changes in the SHV showed significant correlations with changes in the HOOS JR between the preoperative and postoperative periods. The SHV also had substantially fewer ceiling effects compared to the HOOS JR. Conclusions: The SHV is a valid and responsive single-item assessment for hip joint function following primary THA. Despite its limitations, its efficiency and ease of use make it a feasible option for routine clinical assessments, providing clinicians with valuable insights into patients' recovery. Subsequently, the integration of the SHV into orthopedic practice holds promise for enhancing the management of postoperative care and improving patient outcomes.
- 31 October 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 40  (6) , 1413-1418.e1
Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes
- 31 October 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 40  (6) , 1413-1418.e1
Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes